Prevention of valproic acid-induced neural tube defects by sildenafil citrate

Area of Science:

• Developmental toxicology
• Pharmacology
• Teratology

Background:

• Valproic acid (VPA) is a known teratogen, causing significant developmental abnormalities.
• Neural tube defects (NTDs) and skeletal malformations are common VPA-induced teratogenic effects.
• Nitric oxide (NO) signaling pathways are crucial in embryonic development.

Purpose of the Study:

• To investigate the protective effects of sildenafil citrate (SC) against VPA-induced teratogenesis.
• To determine the efficacy of SC in preventing specific developmental defects.
• To explore the role of NO signaling in VPA teratogenicity.

Main Methods:

• Pregnant ICR mice were administered VPA (600mg/kg) to induce teratogenesis.
• Sildenafil citrate (SC) was administered via gastric intubation at various doses (0-10mg/kg) prior to VPA exposure.
• Fetal developmental endpoints, including neural tube and skeletal defects, were evaluated near term.

Main Results:

• VPA exposure resulted in 28% of fetuses exhibiting neural tube defects (exencephaly).
• SC pretreatment (2.5, 5.0, 10mg/kg) significantly reduced exencephaly rates to 15.9%, 13.7%, and 10.0%, respectively.
• SC at 10mg/kg significantly decreased axial skeletal defects from 75.8% to 61.6%.

Conclusions:

• Sildenafil citrate demonstrates significant protective effects against VPA-induced teratogenesis in a mouse model.
• SC's ability to prolong nitric oxide (NO) signaling is implicated in its teratoprotective action.
• These findings highlight SC as a potential therapeutic agent to mitigate VPA-induced developmental abnormalities.